Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 17, 2010, Pages 5269-5273

  Zhong, Min ^a   Shen, Wang ^a   Barr, Kenneth J ^a   Arbitrario, Jennifer P ^a   Arkin, Michelle R ^a   Bui, Minna ^a   Chen, Teresa ^a   Cunningham, Brian C ^a   Evanchik, Marc J ^a   Hanan, Emily J ^a   Hoch, Ute ^a   Huen, Karen ^a   Hyde, Jennifer ^a   Kumer, Jeffery L ^a   Lac, Teresa ^a   Lawrence, Chris E ^a   Martell, Jose R ^a   Oslob, Johan D ^a   Paulvannan, Kumar ^a   Prabhu, Saileta ^a   Silverman, Jeffrey A ^a   Wright, Jasmin ^a   Yu, Chul H ^a   Zhu, Jiang ^a   Flanagan, W Mike ^a   more..

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

Antagonist; Intercellular adhesion molecule 1 (ICAM 1); Leukocyte function associated antigen 1 (LFA 1); Tetrahydroisoquinoline (THIQ) derivative

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TETRAHYDROISOQUINOLINE DERIVATIVE; THIOGLYCOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; PERITONITIS; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DISCOVERY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; TETRAHYDROISOQUINOLINES;

MURINAE; RATTUS;

EID: 77955659802     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.145     Document Type: Article

References (49)

1. E.C. Butcher Cell 67 1991 1033
2. T.A. Springer Annu. Rev. Physiol. 57 1995 827
3. H. Ali, B. Haribabu, R.M. Richardson, and R. Snyderman Med. Clin. North Am. 81 1997 1
4. C.G. Gahmberg Curr. Opin. Cell Biol. 9 1997 643
5. M.P. Bevilacqua, R.M. Nelson, and G. Mannori Annu. Rev. Med. 45 1994 361
6. Y.-W. Huang, R. Baluna, and E.S. Visetta Histol. Hitopathol. 12 1997 467
7. C.J. Cornejo, R.K. Winn, and J.M. Harlan Adv. Pharmacol. 39 1997 99
8. P.A. Henricks, and F.P. Nijkamp Eur. J. Pharmacol. 344 1998 1
9. H. Yusuf-Makagiansar, M.E. Anderson, T.V. Yakovleva, J.S. Murray, and T.J. Siahaan Med. Res. Rev. 22 2002 146
10. M.R. Nicolls, and R.G. Gill Am. J. Transplant. 6 2006 27
11. R.L. Dedrick, P. Walicke, and M. Garovoy Transpl. Immunol. 9 2002 181
12. J.C. Cather, J.C. Cather, and A. Menter Expert Opin. Biol. Ther. 3 2003 361
13. Post-market findings have shown that long term use of efalizumab causes severe side effects, including lymphoma, meningitis, progressive multifocal leukoencephalopathy (PML), and sepsis etc. Recently, Genentech, the manufacturer of the efalizumab, announced that it has begun a voluntary, phased withdrawal of the product from the US market. For more information, see http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149561.htm.
14. T.A. Kelly, D.D. Jeanfavre, D.W. McNeil, J.R. Woska Jr., P.L. Reilly, E.A. Mainolfi, K.M. Kishimoto, G.H. Nabozny, R. Zinter, B.-J. Bormann, and R. Rothlein J. Immunol. 163 1999 5173
15. K. Last-Barney, W. Davidson, M. Cardozo, L.L. Frye, C.A. Grygon, J.L. Hopkins, D.D. Jeanfavre, S. Pav, C. Qian, J.M. Stevenson, L. Tong, R. Zindell, and T.A. Kelly J. Am. Chem. Soc. 123 2001 5643
16. M.J. Panzenbeck, D.D. Jeanfavre, T.A. Kelly, R. Lemieux, G. Nabozny, P.L. Reilly, and S. Desai Eur. J. Pharmacol. 534 2006 233
17. G.O. Caviness, M.E. Labadia, P.A. Giblin, J.R. Woska Jr., K. Last-Barney, D.D. Jeanfavre, and M.M. Morelock Biochem. Phacmacol. 74 2007 98
18. D. Potin, M. Launay, E. Nicolai, M. Fabreguette, P. Malabre, F. Caussade, D. Besse, S. Skala, D.K. Stetsko, G. Todderud, B.R. Beno, D.L. Cheney, C.J. Chang, S. Sheriff, D.L. Hollenbaugh, J.C. Barrish, E.J. Iwanowicz, S.J. Suchard, and T.G. Murali Dhar Bioorg. Med. Chem. Lett. 15 2005 1161
19. D. Potin, M. Launay, F. Monatlik, P. Malabre, M. Fabreguettes, A. Fouquet, M. Maillet, E. Nicolai, L. Dorgeret, F. Chevallier, D. Besse, M. Dufort, F. Caussade, S.Z. Ahmad, D.K. Stetsko, S. Skala, P.M. Davis, P. Balimane, K. Patel, Z. Yang, P. Marathe, J. Postelneck, R.M. Townsend, V. Goldfarb, S. Sheriff, H. Einspahr, K. Kish, M.F. Malley, J.D. DiMarco, J.Z. Gougoutas, P. Kadiyala, D.L. Cheney, R.W. Tejwani, D.K. Murphy, K.W. Mcintyre, X. Yang, S. Chao, L. Leith, Z. Xiao, A. Mathur, B.-C. Chen, D.-R. Wu, S.C. Traeger, M. McKinnon, J.C. Barrish, J.A. Robl, E.J. Iwanowicz, S.J. Suchard, and T.G. Murali Dhar J. Med. Chem. 49 2006 6946
20. D.S. Dodd, S. Sheriff, C.J. Chang, D.K. Stetsko, L.M. Phillips, Y. Zhang, M. Launay, D. Potin, W. Vaccaro, M.A. Poss, M. McKinnon, J.C. Barrish, S.J. Suchard, and T.G. Murali Dhar Bioorg. Med. Chem. Lett. 17 2007 1908
21. S.B. Tran, B.D. Maxwell, S.-Y. Chen, S.J. Bonacorsi, L. Leith, M. Ogan, J.K. Rinehart, and B. Balasubramanian J. Labelled Compd. Rad. 52 2009 236
22. G. Liu, J.T. Link, Z. Pei, E.B. Reilly, S. Leitza, B. Nguyen, K.C. Marsh, G.F. Okasinski, T.W. von Geldern, M. Ormes, K. Fowler, and M. Gallatin J. Med. Chem. 43 2000 4025
23. G. Liu, J.R. Huth, E.T. Olejniczak, R. Mendoza, P. DeVries, S. Leitza, E.B. Reilly, G.F. Okasinski, S.W. Fesik, and T.W. von Geldern J. Med. Chem. 44 2001 1202
24. Z. Pei, Z. Xin, G. Liu, Y. Li, E.B. Reilly, N.L. Lubbers, J.R. Huth, J.T. Link, T.W. von Geldern, B.F. Cox, S. Leitza, Y. Gao, K.C. Marsh, P. DeVries, and G.F. Okasinski J. Med. Chem. 44 2001 2913
25. M. Winn, E.B. Reilly, G. Liu, J.R. Huth, H.-S. Jae, J. Freeman, Z. Pei, Z. Xin, J. Lynch, J. Kester, T.W. von Geldern, S. Leitza, P. DeVries, R. Dickinson, D. Mussatto, and G.F. Okasinski J. Med. Chem. 44 2001 4393
26. J.T. Link, B. Sorensen, G. Liu, Z. Pei, E.B. Reilly, S. Leitza, and G. Okasinski Bioorg. Med. Chem. Lett. 11 2001 973
27. G.T. Wang, S. Wang, R. Gentles, T. Sowin, S. Leitza, E.B. Reilly, and T.W. von Geldern Bioorg. Med. Chem. Lett. 15 2005 195
28. T.R. Gadek, D.J. Burdick, R.S. McDowell, M.S. Stanley, J.C. Marsters Jr., K.J. Paris, D.A. Pare, M.E. Reynolds, C. Ladner, K.A. Zioncheck, W.P. Lee, P. Gribling, M.S. Dennis, N.J. Skelton, D.B. Yumas, K.R. Clark, S.M. Keatinh, M.H. Beresini, J.W. Tilley, L.G. Presta, and S.C. Bodary Science 295 2002 1086
29. D.J. Burdick, K. Paris, K. Weese, M. Stanley, M. Beresini, K. Clark, R.S. McDowell, J.C. Marsters Jr., and T.R. Gadek Bioorg. Med. Chem. Lett. 13 2003 1015
30. D.J. Burdick, J.C. Marsters Jr., I. Aliagas-Martin, M. Stanley, M. Beresini, K. Clark, R.S. McDowell, and T.R. Gadek Bioorg. Med. Chem. Lett. 14 2004 2055
31. S.M. Keating, K.R. Clark, L.D. Stefanich, F. Arellano, C.P. Edwards, S.C. Bodary, S.A. Spencer, T.R. Gadek, J.C. Marsters Jr., and M.H. Beresini Protein Sci. 15 2006 290
32. S.C. Khojasteh, D.D. Leipold, F. Lai, H. La, M.J. Baumgardner, K.E. Desino, O.S. Gudmundsson, D.C. Bloedow, S.C. Bodary, M.E. Reynolds, T.R. Gadek, and S. Kenkare-Mitra Xenobiotica 38 2008 340
33. S. Wattanasin, R. Albert, C. Ehrhardt, D. Roche, M. Sabio, U. Hommel, K. Welzenbach, and G. Weitz-Schmidt Bioorg. Med. Chem. Lett. 13 2003 499
34. S. Wattanasin, J. Kallen, S. Myers, Q. Guo, M. Sabio, C. Ehrhardt, R. Albert, U. Hommel, G. Weckbecker, K. Welzenbach, and G. Weitz-Schmidt Bioorg. Med. Chem. Lett. 15 2005 1217
35. M. Shoda, T. Harada, K. Yano, F.L. Stahura, T. Himeno, S. Shiojiri, Y. Kogami, H. Kouji, and J. Bajorath ChemMedChem 2 2007 515
36. M. Shimaoka, and T.A. Springer Nat. Rev. Drug Discov. 2 2003 703
37. G. Liu Expert Opin. Ther. Pat. 11 2001 1383
38. R. Gniadecki, C. Zachariae, and M. Calverley Acta Derm. Venereol. 82 2002 401
39. There were no LFA-1 antagonists derived from N-benzoyl amino acid advanced to clinical trials reported when we initiated this program in late 2002. SARCode, Inc. in-licensed Sunesis Pharmaceuticals, Inc.'s LFA-1 program in 2007 and has recently completed two Phase II clinical trials of SAR 1118 in patients with dry eyes and/or allergic conjunctivitis. For related press release, please see http://www.sarcode.com/news.html and for information on clinical trial status of SAR 1118, please see http://clinicaltrials.gov/ct2/ results?term=SAR+1118.
40. (a) Burdick, D. J. WIPO Patent Appl. WO1999/49856
41. (b) Burdick, D. J.; Gadek, T. R.; Marsters, J. C., Jr.; Oare, D.; Reynolds, M. E.; Stanley, M. S. WIPO Patent Appl. WO2002/059114.
42. Shen, W.; Barr, K. J.; Oslob, J. D.; Zhong, M. WIPO Patent Appl. WO2005/044817.
43. J.S. Buck J. Am. Chem. Soc. 56 1934 1769
44. D.J. Sall, and G.L. Grunewald J. Med. Chem. 30 1987 2208
45. M. Baker, D.M. Gutman, A.C. Papageorgiou, C.M. Collins, and K.R. Acharya Protein Sci. 10 2001 1268
46. R.J. Neill, M. Jett, R. Crane, J. Wootres, C. Welch, D. Hoover, and P. Gemski Infect. Immun. 64 1996 3007
47. Those active compounds in Hut-78 assay are also less potent in the presence of 10% fetal bovine serum (FBS). This suggests that the decrease of potency is possibly due to serum protein binding.
48. -6 cm/s (A/B and B/A)).
49. D.R. Shaw, and F.M. Griffin Jr. J. Immunol. 128 1982 433